serplulimab   Click here for help

GtoPdb Ligand ID: 13796

Synonyms: HANSIZHUANG® (China) | Hetronifly® | HLX-10 | HLX10
Approved drug Immunopharmacology Ligand
serplulimab is an approved drug
Compound class: Antibody
Comment: Serplulimab (HLX10) is a humanized IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody [1]. It is designed to block the inhibitory PD-1/PD-L1/2 immune checkpoint and restore T cell-mediated anti-tumour immunity.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
Serplulimab (HLX10) inhibits tumour growth in syngeneic and xenograft models [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Primary target of this compound Hs Antibody Binding 8.4 – 8.6 pKd - 1
⤷ pKd 8.6 (Kd 2.42x10-9 M) [1]
Description: Binding affinity for monomeric human PD-1 determined by biolayer interferometry (BLI) assay
pKd 8.4 (Kd 3.7x10-9 M) [1]
Description: Measuring binding affinity for cell-surface expressed PD-1
programmed cell death 1 (CD279) Primary target of this compound Hs Antibody Antagonist 8.2 – 8.4 pIC50 - 1
⤷ pIC50 8.4 (IC50 4.36x10-9 M) [1]
Description: Potency for antagonism of PD-1/PD-L1 binding
pIC50 8.2 (IC50 6.46x10-9 M) [1]
Description: Potency for antagonism of PD-1/PD-L2 binding